DVHGF.US Devonian Health Group Inc.
- Market cap
- USD 13.3M
- P/E
- -
- P/B
- 2.73x
- ROE
- -109.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Apr 2026.
Is DVHGF.US undervalued?
Graham numberThe Graham number of Devonian Health Group Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Devonian Health Group Inc. fundamental analysis
No fundamental analysis for Devonian Health Group Inc. yet.
Devonian Health Group Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Devonian Health Group Inc.
Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS assoc…
Full company profileDevonian Health Group Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Apr 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Devonian Health Group Inc. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 5.94M | 2.14M | 1.47M | 2.31M | 2.35M | 17.8M | 23.6M | 2.29M |
| Gross Profit | - | 3.11M | -70.1K | -241K | 561K | 892K | 5.99M | 8.56M | 1.01M |
| Operating Income | - | -3.19M | -4.60M | -2.26M | -2.87M | -4.28M | -858K | -771K | -7.70M |
| EBITDA | - | -1.81M | -2.81M | -1.23M | -2.01M | -3.72M | -172K | -5.10M | -7.47M |
| Net Income | - | -2.98M | -4.37M | -3.35M | -3.45M | -4.60M | -1.22M | -6.01M | -7.65M |
| EPS | - | -0.04 | -0.06 | -0.04 | -0.03 | -0.03 | -0.01 | -2.43 | -2.75 |
| Balance Sheet | |||||||||
| Total Assets | - | 17.1M | 16.7M | 14.6M | 21.6M | 19.2M | 30.7M | 15.8M | 8.63M |
| Total Liabilities | - | 7.07M | 7.31M | 7.08M | 5.31M | 4.93M | 16.3M | 6.69M | 1.65M |
| Shareholders' Equity | - | 10.1M | 9.38M | 7.52M | 16.3M | 14.2M | 14.5M | 9.14M | 6.98M |
| Cash & Short-term Investments | - | 245K | 913K | 345K | 7.81M | 5.06M | 9.86M | 6.98M | 720K |
| Total Debt | - | - | 4.68M | 5.27M | 4.28M | 3.67M | 2.25M | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | -2.14M | -1.16M | -2.03M | -1.83M | -2.87M | -4.36M | 5.63M | -1.25M | -11.2M |
| Capital Expenditure | 0.00 | 73.7K | 29.5K | 14.1K | 79.4K | 0.00 | 4.25K | 17.4K | 0.00 |
| Free Cash Flow | - | -1.27M | -2.06M | -1.85M | -2.95M | -4.36M | 5.63M | -1.27M | -11.2M |
| Ratios | |||||||||
| ROE | - | -29.6% | -46.6% | -44.5% | -21.2% | -32.3% | -8.5% | -65.8% | -109.6% |
| ROA | - | -17.4% | -26.2% | -22.9% | -16.0% | -24.0% | -4.0% | -38.0% | -88.7% |
| Net Profit Margin | - | -50.2% | -204.1% | -226.9% | -149.6% | -196.1% | -6.9% | -25.5% | -334.2% |
| Debt to Equity | - | - | 0.50x | 0.70x | 0.26x | 0.26x | 0.16x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Devonian Health Group Inc. dividends
Devonian Health Group Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 1:60 on Jan 22, 2026.
Who owns Devonian Health Group Inc.
- Insiders 12.04%
- Institutions 0.29%
- Public & others 87.67%
- Shares outstanding 2.78M
- Free float 2.11M
Devonian Health Group Inc. company profile
- Company name
- Devonian Health Group Inc.
- Ticker
- DVHGF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- July
- Address
- 360, rue des Entrepreneurs, Québec, QC, Canada, G5V 4T1
- Phone
- 581-632-0692
- Website
- groupedevonian.com
About Devonian Health Group Inc.
Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops pantoprazole magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the purgenesis name. Devonian Health Group Inc. was founded in 2017 and is headquartered in Québec, Canada.
Devonian Health Group Inc. management
3- Dr. Andre P. Boulet Ph.D.Chair of the Board & CEO · born 1959
- Mr. Dennis Turpin CA, CPACFO & Director · born 1963
- Mr. Luc D. Gregoire CA, CPAExecutive Vice-President of Strategy · born 1960